FINANCE/FUNDING ARTICLES

• In A Tighter VC Environment, Biopharmas Need To Get Valuation Right

  The rigor investors are demanding from emerging companies means that life sciences entrepreneurs need to double down on having clear and concise milestones and good strategic plans — a challenging proposition, especially for early-stage companies that typically do not have suitable market comparisons.

• Milestone Payments In Life Sciences M&A And Licensing Transactions

  Now is an opportune time to take a fresh look at some key considerations regarding a common feature of M&As — payments that become due in the future upon the achievement of specified events, which are commonly known as “milestones.”

• Key Considerations In Early-Stage Biopharma Financing

  After over two years of soaring IPO valuations and high stock prices, biotech had a reckoning in the back half of 2021.

• Is Biopharma Poised For Bigger Deals In 2022?

  Biopharma companies are sitting on roughly $1.2 trillion in firepower, according to a recent report by Ernst & Young. But firepower to spend on deals — which includes cash, existing debt, and market capitalization — won’t necessarily translate into multibillion-dollar transactions, at least in the short term.

• Embracing Challenges And Executing A Successful IPO

  John Jacobs, CEO of Harmony Biosciences, discusses the challenges and lessons learned from when his company transitioned from private to public.

• A Q&A With A Venture Capitalist/Genetic Medicines Executive

  Small biotech companies can improve their fundraising prowess, despite choppy market conditions, by avoiding a few common mistakes. Telling a good story is the first step.

• Why Biotechs Need A Practical Approach To Going Public

  Biotechs, in particular, should be mindful of the ramifications of the avenue they choose to go public. Here’s a look at three options and their challenges.

• Turbocharging Early-Stage Biotech Growth With Venture Debt

  A growing number of early-stage companies are making strategic use of venture-debt financing to cover short-term cash needs, providing a longer cash runway that helps cover ongoing costs of product development and commercialization without diluting equity.

• Why It’s Never Too Early To Develop Your Exit Strategy

  It’s important to consider an exit strategy early in your process instead of waiting until there are challenges with liquidity, profitability, efficiency, lack of succession planning, and different partner expectations that would call for you to exit.

• Gearing Up For A Biotech M&A Boom

  Biotech M&A was slow in the first half of 2021, but that may be changing, with emerging trends indicating that a biotech M&A boom could be on the horizon. If your biotech is hoping to be acquired by a larger pharma company, it’s crucial that you start preparing now.